Skip to main content

NovoCure Ltd

corporate_fare Company Profile

NovoCure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Exchange: NASDAQSector: Industrial Applications And Services

show_chartPrice Chart

Loading chart...

feed NVCR - Latest Insights

NVCR
Apr 20, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
7
NVCR
Mar 26, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
NVCR
Mar 02, 2026, 8:02 AM EST
Source: dpa-AFX
Importance Score:
8
NVCR
Feb 26, 2026, 7:01 AM EST
Filing Type: 10-K
Importance Score:
8
NVCR
Feb 26, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
NVCR
Feb 24, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
9
NVCR
Feb 11, 2026, 5:24 PM EST
Filing Type: 8-K
Importance Score:
9
NVCR
Feb 05, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
9
NVCR
Jan 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8